SRPT Stock Price Today (October 2026) — Sarepta Therapeutics, Inc. Analysis & Key Metrics 2026-10-07
Sarepta Therapeutics, Inc. (SRPT) is trading at $17.50, up 1.10% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $21.73 (24.2% upside).
- Volatility is high (40.78% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-34.30% YoY) alongside competitive pressures in the Biotechnology space.
SRPT Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Sarepta Therapeutics, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $2.12B
P/E Ratio
Forward P/E: 8.19
Revenue Growth
Year over Year
Analyst Target
+24.2% upside potential
Key Investor Questions About SRPT
What investors need to know before buying
Based on current market data, SRPT presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 34.18)
- Fundamentals say: Challenging (declining revenue trends)
SRPT's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for SRPT investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.06B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, SRPT stock traded between $14.68 and $25.32 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 40.78% annualized volatility and β=1.80, the stock exhibits high sensitivity to market moves—making SRPT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie
Novartis Stock Tanks Following Third Major Pipeline Setback
Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on...
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value
Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation checks giving a mixed signal, investors are left weighing recent performance against the current pricing. The share price decline of around 84.7% over the past 3 years points to a company where expectations have reset sharply and long term holders have faced heavy losses. Future progress in Sarepta...
Moderna Stock Had A Readout Waiting In Plain Sight
Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
Explore More Analysis for SRPT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) is currently trading at $17.50. The RSI (14-day) is at 34.2, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $21.73 implies 24.2% upside from current levels. Volatility is high at 40.8% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Sarepta Therapeutics, Inc. (SRPT): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 8.19. Price-to-Book is 1.45. Price-to-Sales is 1.12. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering SRPT, the consensus price target is $21.73. This represents a 24.2% upside from the current price of $17.50. The range spans from a low target of $5.00 to a high target of $38.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Sarepta Therapeutics, Inc. (SRPT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Sarepta Therapeutics, Inc. (SRPT) investors include: 1. High volatility (40.8% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-34.3% YoY), indicating potential business headwinds. 4. Elevated short interest (28.9% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Sarepta Therapeutics, Inc.'s (SRPT) current debt and financial health profile: Total debt stands at $1.06B. The debt-to-equity ratio is 0.70x, which is moderate and generally manageable for most companies. The current ratio is 4.42, indicating strong short-term liquidity. The quick ratio is 2.44. The company holds $788.49M in cash and equivalents. Free cash flow is positive at $22.14M, providing a cushion for debt servicing and shareholder returns.